|
| Anticoagulant therapies | Effect estimates of indices of hepatic damage |
| ALT | AST | Albumin | Total bilirubin |
|
| Antiplatelet agents | MD −242.29, 95% CI (−409.06, −75.51) | | MD −1195.30, 95% CI (−1356.24, −1034.36) | | MD 1.10, 95% CI (0.86, 1.34) | | MD −1.79, 95% CI (−2.00, −1.59) | |
|
| LMWHs | MD −10.41, 95% CI (−24.45, 3.63) | | MD −25.17, 95% CI (−46.52, −3.83) | | MD −0.01, 95% CI (−0.19, 0.17) | | MD −1.16, 95% CI (−2.18, −0.13) | |
|
| Factor Xa inhibitor (rivaroxaban) | MD −133.66, 95% CI (−412.73, 145.40) | | MD −329.49, 95% CI (−1053.49, 394.52) | | MD 0.90, 95% CI (0.66, 1.13) | | MD −0.57, 95% CI (−1.69, 0.54) | |
|
| Standard heparin | MD −47.46, 95% CI (−107.27, 12.34) | | MD 23.42, 95% CI (−26.43, 73.27) | | MD 1.77, 95% CI (0.10, 3.44) | | MD 1.34, 95% CI (0.01, 2.67) | |
|
| Thrombin inhibitor | MD −300.97, 95% CI (−864.44, 262.71) | | MD −486.86, 95% CI (−1505.52, 531.81) | | MD 1.00, 95% CI (0.77, 1.23) | | MD −0.90, 95% CI (−2.56, 0.77) | |
|
